A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) in Combination With Low Dose Cytarabine in Subjects With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) in Combination With Low Dose Cytarabine in Subjects With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to determine the safety and effectiveness of ulocuplumab in combination with low dose cytarabine in the treatment of Newly Diagnosed Acute Myeloid Leukemia (AML).
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Porto Alegre, Rio Grande do Sul 90110-270, Brazil
Fukuyama-shi, Hiroshima 7200001, Japan
Hirakata-shi, Osaka 5731191, Japan
Bunkyo-ku, Tokyo 1138677, Japan
Shinagawa-ku, Tokyo 1418625, Japan
Shinjuku-Ku, Tokyo 1608582, Japan